Fiibo, a Brazilian healthfintech providing digital infrastructure for the health insurance market, has closed a seed round extension led by Vox Capital through its co-investment fund with Hospital Israelita Albert Einstein and by Criabiz Ventures. The undisclosed amount complements the R$17.5 million seed round raised in 2023 with Headline and Vox Capital. The new capital supports the company's move into health retail and prepares it for a Series A planned for 2027.
Investor Support and Strategic Backing
Vox Capital and Headline, which participated in the original seed round, increased their stakes during the extension. Criabiz Ventures led the new stage alongside Vox Capital, while IKJ Capital and 040 Ventures also joined the round. The participation of these investors signals confidence in Fiibo's mission to modernize Brazil's supplemental health market.
From B2B Expansion to Open Health Retail
Founded in 2022, Fiibo initially focused on large companies before expanding to smaller players. The startup has now opened its marketplace to individuals and microentrepreneurs, moving into the health retail segment. Its website displays health plan prices openly, a shift the company compares to the transparency XP brought to Brazil's investment market twenty years ago.
The company emphasizes that the new marketplace model does not eliminate brokers. Instead, brokers become advisors when clients need orientation, similar to professionals on investment platforms. This approach directly targets the high distribution costs and deep friction that have long made health plan sales heavily intermediated, document intensive, and difficult for consumers to navigate across Brazil.
Operational Momentum and Market Traction
Fiibo reached operational breakeven in July 2026 and now serves 3,500 companies, representing approximately 200,000 lives. Revenue grew more than eight times in the first six months of this year, according to founder and CEO Ítalo Martins. The platform lists more than 4,000 products from over 400 suppliers, including operators such as Hapvida, Doctor Clin, and Hospitalar.
Martins said the market increasingly seeks out Fiibo to modernize distribution, comparing the platform to the Mercado Livre or iFood of health. Recent executive hires from traditional industry players reinforce that perception, he added. Both executives had previously contracted Fiibo before joining the startup, demonstrating the product's relevance among established companies.
Capital Allocation and Series A Ambitions
The fresh capital will be used to accelerate technological infrastructure, expand distribution channels, and complete contracts already in the commercial pipeline. Fiibo expects to raise a more substantial Series A round in 2027 once its retail operation matures and builds a stronger revenue track record. The company also maintains distribution partnerships with companies such as XP, Vivo, Serasa, ABRH Brasil, CDLs, and Flamengo.
Fiibo is positioning itself as an infrastructure layer in Brazil's health sector at a time when plan pricing remains largely offline and difficult to compare. The seed extension provides runway to strengthen its platform and prove the consumer marketplace model. The planned 2027 Series A will be a key test of whether the company can scale this digital transformation across a traditionally resistant industry.